{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:19:50Z","timestamp":1794316790717,"version":"4.9.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early therapeutic interventions are essential to prevent Alzheimer Disease (AD). The association of several inflammation-related genetic markers with AD and the early activation of pro-inflammatory pathways in AD suggest inflammation as a plausible therapeutic target. Inflammatory Caspase-1 has a significant impact on AD-like pathophysiology and Caspase-1 inhibitor, VX-765, reverses cognitive deficits in AD mouse models. Here, a one-month pre-symptomatic treatment of Swedish\/Indiana mutant amyloid precursor protein (APP\n                    <jats:sup>Sw\/Ind<\/jats:sup>\n                    ) J20 and wild-type mice with VX-765 delays both APP\n                    <jats:sup>Sw\/Ind<\/jats:sup>\n                    - and age-induced episodic and spatial memory deficits. VX-765 delays inflammation without considerably affecting soluble and aggregated amyloid beta peptide (A\u03b2) levels. Episodic memory scores correlate negatively with microglial activation. These results suggest that Caspase-1-mediated inflammation occurs early in the disease and raise hope that VX-765, a previously Food and Drug Administration-approved drug for human CNS clinical trials, may be a useful drug to prevent the onset of cognitive deficits and brain inflammation in AD.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-18405-9","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T06:09:21Z","timestamp":1599804561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4790-3034","authenticated-orcid":false,"given":"Joseph","family":"Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-3828","authenticated-orcid":false,"given":"Anastasia","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Foveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Beauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-3900","authenticated-orcid":false,"given":"Andr\u00e9a C.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"18405_CR1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings, J., Lee, G., Ritter, A., Sabbagh, M. & Zhong, K. Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement 5, 272\u2013293 (2019).","journal-title":"Alzheimers Dement"},{"key":"18405_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol. 9, 702\u2013716 (2010).","journal-title":"Lancet Neurol."},{"key":"18405_CR3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","volume":"559","author":"S Makin","year":"2018","unstructured":"Makin, S. The amyloid hypothesis on trial. Nature 559, S4\u2013S7 (2018).","journal-title":"Nature"},{"key":"18405_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399\u2013415 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"18405_CR5","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-179","volume":"9","author":"DH Cribbs","year":"2012","unstructured":"Cribbs, D. H. et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflammation 9, 179 (2012).","journal-title":"J. Neuroinflammation"},{"key":"18405_CR6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nn.4222","volume":"19","author":"K Grabert","year":"2016","unstructured":"Grabert, K. et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 19, 504\u2013516 (2016).","journal-title":"Nat. Neurosci."},{"key":"18405_CR7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/glia.10319","volume":"45","author":"WJ Streit","year":"2004","unstructured":"Streit, W. J., Sammons, N. W., Kuhns, A. J. & Sparks, D. L. Dystrophic microglia in the aging human brain. Glia 45, 208\u2013212 (2004).","journal-title":"Glia"},{"key":"18405_CR8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759\u2013772 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"18405_CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat. Genet. 51, 414\u2013430 (2019).","journal-title":"Nat. Genet."},{"key":"18405_CR10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","volume":"345","author":"BA in t\u2019 Veld","year":"2001","unstructured":"in t\u2019 Veld, B. A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer\u2019s disease. N. Engl. J. Med. 345, 1515\u20131521 (2001).","journal-title":"N. Engl. J. Med."},{"key":"18405_CR11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0197-4580(01)00299-8","volume":"22","author":"GP Lim","year":"2001","unstructured":"Lim, G. P. et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983\u2013991 (2001).","journal-title":"Neurobiol. Aging"},{"key":"18405_CR12","doi-asserted-by":"crossref","unstructured":"Jaturapatporn, D., Isaac, M. G., McCleery, J. & Tabet, N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst. Rev. CD006378 (2012).","DOI":"10.1002\/14651858.CD006378.pub2"},{"key":"18405_CR13","doi-asserted-by":"crossref","first-page":"e2070","DOI":"10.1212\/WNL.0000000000007232","volume":"92","author":"PF Meyer","year":"2019","unstructured":"Meyer, P. F. et al. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology 92, e2070\u2013e2080 (2019).","journal-title":"Neurology"},{"key":"18405_CR14","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12504","volume":"7","author":"MJ Daniels","year":"2016","unstructured":"Daniels, M. J. et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models. Nat. Commun. 7, 12504 (2016).","journal-title":"Nat. Commun."},{"key":"18405_CR15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka, M. T. et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature 493, 674\u2013678 (2013).","journal-title":"Nature"},{"key":"18405_CR16","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/cdd.2015.16","volume":"22","author":"V Kaushal","year":"2015","unstructured":"Kaushal, V. et al. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 22, 1676\u20131686 (2015).","journal-title":"Cell Death Differ."},{"key":"18405_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer\u2019s disease. Nature 552, 355\u2013361 (2017).","journal-title":"Nature"},{"key":"18405_CR18","volume":"5","author":"MS Tan","year":"2014","unstructured":"Tan, M. S. et al. Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer\u2019s disease. Cell Death Dis. 5, e1382 (2014).","journal-title":"Cell Death Dis."},{"key":"18405_CR19","volume":"9","author":"J Flores","year":"2018","unstructured":"Flores, J. et al. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer\u2019s disease mouse model. Nat. Commun. 9, 3916 (2018).","journal-title":"Nat. Commun."},{"key":"18405_CR20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.neurobiolaging.2011.09.040","volume":"33","author":"JI Diaz-Hernandez","year":"2012","unstructured":"Diaz-Hernandez, J. I. et al. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer\u2019s disease through GSK3beta and secretases. Neurobiol. Aging 33, 1816\u20131828 (2012).","journal-title":"Neurobiol. Aging"},{"key":"18405_CR21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/ejn.12250","volume":"37","author":"AC LeBlanc","year":"2013","unstructured":"LeBlanc, A. C. Caspase-6 as a novel early target in the treatment of Alzheimer\u2019s disease. Eur. J. Neurosci. 37, 2005\u20132018 (2013).","journal-title":"Eur. J. Neurosci."},{"key":"18405_CR22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9440(10)63317-2","volume":"165","author":"H Guo","year":"2004","unstructured":"Guo, H. et al. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer\u2019s disease. Am. J. Pathol. 165, 523\u2013531 (2004).","journal-title":"Am. J. Pathol."},{"key":"18405_CR23","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1523\/JNEUROSCI.5874-09.2010","volume":"30","author":"D Halawani","year":"2010","unstructured":"Halawani, D. et al. Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer\u2019s disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J. Neurosci. 30, 6132\u20136142 (2010).","journal-title":"J. Neurosci."},{"key":"18405_CR24","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1074\/mcp.M800007-MCP200","volume":"7","author":"G Klaiman","year":"2008","unstructured":"Klaiman, G., Petzke, T. L., Hammond, J. & Leblanc, A. C. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell Proteom. 7, 1541\u20131555 (2008).","journal-title":"Mol. Cell Proteom."},{"key":"18405_CR25","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.74","volume":"1","author":"SN Sivananthan","year":"2010","unstructured":"Sivananthan, S. N., Lee, A. W., Goodyer, C. G. & LeBlanc, A. C. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid beta-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death Dis. 1, e100 (2010).","journal-title":"Cell Death Dis."},{"key":"18405_CR26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/cdd.2013.194","volume":"21","author":"AC LeBlanc","year":"2014","unstructured":"LeBlanc, A. C. et al. Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death Differ. 21, 696\u2013706 (2014).","journal-title":"Cell Death Differ."},{"key":"18405_CR27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s40478-019-0856-6","volume":"7","author":"L Zhou","year":"2019","unstructured":"Zhou, L. et al. Methylene blue inhibits Caspase-6 activity, and reverses Caspase-6-induced cognitive impairment and neuroinflammation in aged mice. Acta Neuropathol. Commun. 7, 210 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"18405_CR28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41418-017-0043-x","volume":"25","author":"A Noel","year":"2018","unstructured":"Noel, A., Zhou, L., Foveau, B., Sjostrom, P. J. & LeBlanc, A. C. Differential susceptibility of striatal, hippocampal and cortical neurons to Caspase-6. Cell Death Differ. 25, 1319\u20131335 (2018).","journal-title":"Cell Death Differ."},{"key":"18405_CR29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2353\/ajpath.2007.060974","volume":"170","author":"S Albrecht","year":"2007","unstructured":"Albrecht, S. et al. Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 170, 1200\u20131209 (2007).","journal-title":"Am. J. Pathol."},{"key":"18405_CR30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.neurobiolaging.2013.01.007","volume":"34","author":"J Ramcharitar","year":"2013","unstructured":"Ramcharitar, J., Afonso, V. M., Albrecht, S., Bennett, D. A. & LeBlanc, A. C. Caspase-6 activity predicts lower episodic memory ability in aged individuals. Neurobiol. Aging 34, 1815\u20131824 (2013).","journal-title":"Neurobiol. Aging"},{"key":"18405_CR31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138161207780163006","volume":"13","author":"S Cornelis","year":"2007","unstructured":"Cornelis, S., Kersse, K., Festjens, N., Lamkanfi, M. & Vandenabeele, P. Inflammatory caspases: targets for novel therapies. Curr. Pharm. Des. 13, 367\u2013385 (2007).","journal-title":"Curr. Pharm. Des."},{"key":"18405_CR32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature12940","volume":"505","author":"G Doitsh","year":"2014","unstructured":"Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509\u2013514 (2014).","journal-title":"Nature"},{"key":"18405_CR33","doi-asserted-by":"crossref","first-page":"E6065","DOI":"10.1073\/pnas.1722041115","volume":"115","author":"BA McKenzie","year":"2018","unstructured":"McKenzie, B. A. et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl Acad. Sci. USA 115, E6065\u2013E6074 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18405_CR34","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.1610099113","volume":"113","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein alpha-synuclein. Proc. Natl Acad. Sci. USA 113, 9587\u20139592 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18405_CR35","doi-asserted-by":"crossref","first-page":"9593","DOI":"10.1073\/pnas.1609291113","volume":"113","author":"F Bassil","year":"2016","unstructured":"Bassil, F. et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc. Natl Acad. Sci. USA 113, 9593\u20139598 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"18405_CR36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cmdc.200900531","volume":"5","author":"MB Boxer","year":"2010","unstructured":"Boxer, M. B. et al. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. ChemMedChem 5, 730\u2013738 (2010).","journal-title":"ChemMedChem"},{"key":"18405_CR37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.5341-09.2010","volume":"30","author":"JA Harris","year":"2010","unstructured":"Harris, J. A. et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer\u2019s disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 30, 372\u2013381 (2010).","journal-title":"J. Neurosci."},{"key":"18405_CR38","doi-asserted-by":"crossref","first-page":"e59586","DOI":"10.1371\/journal.pone.0059586","volume":"8","author":"AL Wright","year":"2013","unstructured":"Wright, A. L. et al. Neuroinflammation and neuronal loss precede A\u03b2 plaque deposition in the hAPP-J20 mouse model of Alzheimer\u2019s disease. PLoS ONE 8, e59586 (2013).","journal-title":"PLoS ONE"},{"key":"18405_CR39","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.4397","volume":"23","author":"MW Salter","year":"2017","unstructured":"Salter, M. W. & Stevens, B. Microglia emerge as central players in brain disease. Nat. Med. 23, 1018\u20131027 (2017).","journal-title":"Nat. Med."},{"key":"18405_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00040-0","volume":"57","author":"D Ito","year":"1998","unstructured":"Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol. Brain Res. 57, 1\u20139 (1998).","journal-title":"Brain Res Mol. Brain Res."},{"key":"18405_CR41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2353\/ajpath.2010.090915","volume":"177","author":"Z Ahmed","year":"2010","unstructured":"Ahmed, Z. et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 177, 311\u2013324 (2010).","journal-title":"Am. J. Pathol."},{"key":"18405_CR42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.4049\/jimmunol.149.4.1294","volume":"149","author":"D Perregaux","year":"1992","unstructured":"Perregaux, D. et al. IL-1\u03b2 maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J. Immunol. 149, 1294\u20131303 (1992).","journal-title":"J. Immunol."},{"key":"18405_CR43","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.4049\/jimmunol.144.6.2179","volume":"144","author":"HU Beuscher","year":"1990","unstructured":"Beuscher, H. U., Gunther, C. & Rollinghoff, M. IL-1\u03b2 is secreted by activated murine macrophages as biologically inactive precursor. J. Immunol. 144, 2179\u20132183 (1990).","journal-title":"J. Immunol."},{"key":"18405_CR44","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"L Mucke","year":"2000","unstructured":"Mucke, L. et al. High-level neuronal expression of a\u03b2 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050\u20134058 (2000).","journal-title":"J. Neurosci."},{"key":"18405_CR45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/72237","volume":"6","author":"N Iwata","year":"2000","unstructured":"Iwata, N. et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143\u2013150 (2000).","journal-title":"Nat. Med."},{"key":"18405_CR46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)00387-4","volume":"345","author":"IV Kurochkin","year":"1994","unstructured":"Kurochkin, I. V. & Goto, S. Alzheimer\u2019s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345, 33\u201337 (1994).","journal-title":"FEBS Lett."},{"key":"18405_CR47","doi-asserted-by":"crossref","unstructured":"Flurkey, K. M., Currer, J. & Harrison, D. E. in The Mouse in Biomedical Research (second edn) (eds Fox, J. G. et al.) 637\u2013672 (Academic Press, 2007).","DOI":"10.1016\/B978-012369454-6\/50074-1"},{"key":"18405_CR48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euroneuro.2005.06.005","volume":"16","author":"D Van Dam","year":"2006","unstructured":"Van Dam, D. & De Deyn, P. P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur. Neuropsychopharmacol. 16, 59\u201369 (2006).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"18405_CR49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropharm.2017.11.042","volume":"130","author":"LM Smith","year":"2018","unstructured":"Smith, L. M., Zhu, R. & Strittmatter, S. M. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer\u2019s model. Neuropharmacology 130, 54\u201361 (2018).","journal-title":"Neuropharmacology"},{"key":"18405_CR50","doi-asserted-by":"crossref","first-page":"23426","DOI":"10.1074\/jbc.274.33.23426","volume":"274","author":"A LeBlanc","year":"1999","unstructured":"LeBlanc, A., Liu, H., Goodyer, C., Bergeron, C. & Hammond, J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer\u2019s disease. J. Biol. Chem. 274, 23426\u201323436 (1999).","journal-title":"J. Biol. Chem."},{"key":"18405_CR51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbamcr.2008.12.004","volume":"1793","author":"G Klaiman","year":"2009","unstructured":"Klaiman, G., Champagne, N. & LeBlanc, A. C. Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. Biochim Biophys. Acta 1793, 592\u2013601 (2009).","journal-title":"Biochim Biophys. Acta"},{"key":"18405_CR52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.gt.3302126","volume":"11","author":"BH Liu","year":"2004","unstructured":"Liu, B. H., Wang, X., Ma, Y. X. & Wang, S. CMV enhancer\/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther. 11, 52\u201360 (2004).","journal-title":"Gene Ther."},{"key":"18405_CR53","doi-asserted-by":"crossref","unstructured":"Milikovsky, D. Z. et al. Paroxysmal slow cortical activity in Alzheimer\u2019s disease and epilepsy is associated with blood-brain barrier dysfunction. Sci. Transl. Med. 11, eaaw8954 (2019).","DOI":"10.1126\/scitranslmed.aaw8954"},{"key":"18405_CR54","doi-asserted-by":"crossref","unstructured":"Senatorov, V. V., Jr. et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFbeta signaling and chronic yet reversible neural dysfunction. Sci. Transl. Med. 11, eaaw8283 (2019).","DOI":"10.1126\/scitranslmed.aaw8283"},{"key":"18405_CR55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","volume":"908","author":"C Franceschi","year":"2000","unstructured":"Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y Acad. Sci. 908, 244\u2013254 (2000).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"18405_CR56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.neurobiolaging.2005.03.013","volume":"27","author":"MG Frank","year":"2006","unstructured":"Frank, M. G. et al. mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol. Aging 27, 717\u2013722 (2006).","journal-title":"Neurobiol. Aging"},{"key":"18405_CR57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbi.2008.09.002","volume":"23","author":"CJ Henry","year":"2009","unstructured":"Henry, C. J., Huang, Y., Wynne, A. M. & Godbout, J. P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav. Immun. 23, 309\u2013317 (2009).","journal-title":"Brain Behav. Immun."},{"key":"18405_CR58","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","volume":"215","author":"D Boucher","year":"2018","unstructured":"Boucher, D. et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med. 215, 827\u2013840 (2018).","journal-title":"J. Exp. Med."},{"key":"18405_CR59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"A Halle","year":"2008","unstructured":"Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857\u2013865 (2008).","journal-title":"Nat. Immunol."},{"key":"18405_CR60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.106.111344","volume":"321","author":"W Wannamaker","year":"2007","unstructured":"Wannamaker, W. et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1\u03b2 and IL-18. J. Pharmacol. Exp. Ther. 321, 509\u2013516 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"18405_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.86","volume":"3","author":"A Denes","year":"2012","unstructured":"Denes, A., Lopez-Castejon, G. & Brough, D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis. 3, e338 (2012).","journal-title":"Cell Death Dis."},{"key":"18405_CR62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"18405_CR63","doi-asserted-by":"crossref","first-page":"23818","DOI":"10.1074\/jbc.M701078200","volume":"282","author":"IH Cheng","year":"2007","unstructured":"Cheng, I. H. et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818\u201323828 (2007).","journal-title":"J. Biol. Chem."},{"key":"18405_CR64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3233\/JAD-142208","volume":"44","author":"AM Foley","year":"2015","unstructured":"Foley, A. M., Ammar, Z. M., Lee, R. H. & Mitchell, C. S. Systematic review of the relationship between amyloid-beta levels and measures of transgenic mouse cognitive deficit in Alzheimer\u2019s disease. J. Alzheimers Dis. 44, 787\u2013795 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"18405_CR65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett, D. A. et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837\u20131844 (2006).","journal-title":"Neurology"},{"key":"18405_CR66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrneurol.2013.21","volume":"9","author":"G Chetelat","year":"2013","unstructured":"Chetelat, G. Alzheimer disease: A\u03b2-independent processes-rethinking preclinical AD. Nat. Rev. Neurol. 9, 123\u2013124 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"18405_CR67","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ana.23816","volume":"73","author":"DS Knopman","year":"2013","unstructured":"Knopman, D. S. et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann. Neurol. 73, 472\u2013480 (2013).","journal-title":"Ann. Neurol."},{"key":"18405_CR68","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"18405_CR69","doi-asserted-by":"crossref","unstructured":"Gallardo, G. & Holtzman, D. M. Antibody therapeutics targeting A\u03b2 and Tau. Cold Spring Harb. Perspect. Med. 7, a024331 (2017).","DOI":"10.1101\/cshperspect.a024331"},{"key":"18405_CR70","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/brain\/awn008","volume":"131","author":"LA Kotilinek","year":"2008","unstructured":"Kotilinek, L. A. et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651\u2013664 (2008).","journal-title":"Brain"},{"key":"18405_CR71","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/brain\/aww117","volume":"139","author":"NS Woodling","year":"2016","unstructured":"Woodling, N. S. et al. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer\u2019s disease model mice. Brain 139, 2063\u20132081 (2016).","journal-title":"Brain"},{"key":"18405_CR72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2818.1987.tb02837.x","volume":"147","author":"HJ Gundersen","year":"1987","unstructured":"Gundersen, H. J. & Jensen, E. B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc 147, 229\u2013263 (1987).","journal-title":"J. Microsc"},{"key":"18405_CR73","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"18405_CR74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.7326\/0003-4819-100-1-122","volume":"100","author":"LA Cupples","year":"1984","unstructured":"Cupples, L. A., Heeren, T., Schatzkin, A. & Colton, T. Multiple testing of hypotheses in comparing two groups. Ann. Intern. Med. 100, 122\u2013129 (1984).","journal-title":"Ann. Intern. Med."}],"updated-by":[{"DOI":"10.1038\/s41467-021-22789-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18405-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:18:01Z","timestamp":1723555081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18405-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18405"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18405-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-021-22789-7","URL":"https:\/\/doi.org\/10.1038\/s41467-021-22789-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4571"}}